Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01217437
Title Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

medulloblastoma

pineoblastoma

Therapies

Irinotecan + Temozolomide

Bevacizumab + Irinotecan + Temozolomide

Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.